Sure, having a cold or respiratory infection can temporarily make it harder to breathe. But if excessive coughing and ...

3/4 inhibitor – now given the somewhat tongue-twisting brand name of Ohtuvayre – is the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD ...

With the latest nod from the US Food and Drug Administration (FDA), Regeneron Pharmaceuticals and Sanofi have expanded the US label of Dupixent (dupilumab) to treat chronic obstructive pulmonary ...

Currently, COPD-marketed therapy leaders include GSK’s Trelegy Ellipta, which is set to grow in sales to $2.16bn by 2033.

Regeneron and Sanofi on Friday said the green light covers Dupixent as an add-on maintenance treatment in certain adults with uncontrolled chronic obstructive pulmonary disease, or COPD ...

Asthma is a chronic (long-term) lung condition in which airways can become inflamed and narrowed. This makes it difficult to ...

Dupixent has gained positive opinions from KOLs due to the positive data presented from the asset’s two Phase III clinical ...

Dupilumab, a fully human monoclonal antibody sold under the brand name, Dupixent ... dupilumab is a welcome addition to the COPD-treatment armamentarium, he said. The approval was based on ...

Analysts expect the partners’ first-mover advantage, clinical data and existing presence in lung disease to translate into ...

Opens in a new tab or window “Compared to non-CMR recipients, CMR recipients experienced a considerably higher increase in adherence to COPD medications from 2016 to 2017, and findings with data ...

Study objectives: To identify the predictors of medication adherence in patients with COPD and contrast the health beliefs, experiences, and behaviors of COPD patients self-reporting good ...

Klaus Rabe, MD, PhD, chest physician and professor of medicine, University of Kiel, discusses the potential of tailored treatment strategies and the importance of smoking cessation.